Grant: Banting Postdoctoral Fellowship Program
Direct Payment
$140,000.00
Non-invasive isolation and expansion of polyclonal tumor-reactive lymphocytes from peripheral blood for cancer immunotherapy
FY 2022-23
Summary
Cancer is the leading cause of death in Canada. An estimated 2 in 5 Canadian will be diagnosed with cancer in their lifetime according to Canadian Cancer Statistics 2021. It is urgent to develop a cancer therapy that is efficient, durable, and affordable. Our immune cells play a critical role in fighting cancer. Indeed, research has shown that immune cells residing in the growing tumor have strong anti-tumor activity. The recovery and expansion of these cells have shown remarkable therapeutic outcomes in the clinic, where subsets of melanoma patients were fully cured and remained cancer-free for years.
However, the recovery of tumor-residing immune cells requires an invasive surgical procedure that is not applicable to every patient. Encouragingly, I recently discovered an immune cell population in blood circulation that is highly effective in killing tumor cells. In this project, I will deploy an engineered microchip technology to efficiently isolate these anti-tumor immune cells directly from the patient's blood, instead of surgically removed tumors. I will evaluate the anti-tumor efficacy of isolated cells with multiple animal models. Because blood collection is much gentler and more amenable compared to tumor removal, my research will prime a new generation of cancer therapy that is durable, non-invasive, and broadly applicable to every cancer patient in Canada and worldwide.
Department
Program
Banting Postdoctoral Fellowship Program
Recipient
Location
Illinois, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
471350
Name
Wang Zongjie
Region
Illinois
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Non-invasive isolation and expansion of polyclonal tumor-reactive lymphocytes from peripheral blood for cancer immunotherapy
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Cancer Immunotherapy; Cellular Therapy; Microfluidics; Nanotechnology; Tumor Immunology
Abstract
Cancer is the leading cause of death in Canada. An estimated 2 in 5 Canadian will be diagnosed with cancer in their lifetime according to Canadian Cancer Statistics 2021. It is urgent to develop a cancer therapy that is efficient, durable, and affordable. Our immune cells play a critical role in fighting cancer. Indeed, research has shown that immune cells residing in the growing tumor have strong anti-tumor activity. The recovery and expansion of these cells have shown remarkable therapeutic outcomes in the clinic, where subsets of melanoma patients were fully cured and remained cancer-free for years.
However, the recovery of tumor-residing immune cells requires an invasive surgical procedure that is not applicable to every patient. Encouragingly, I recently discovered an immune cell population in blood circulation that is highly effective in killing tumor cells. In this project, I will deploy an engineered microchip technology to efficiently isolate these anti-tumor immune cells directly from the patient's blood, instead of surgically removed tumors. I will evaluate the anti-tumor efficacy of isolated cells with multiple animal models. Because blood collection is much gentler and more amenable compared to tumor removal, my research will prime a new generation of cancer therapy that is durable, non-invasive, and broadly applicable to every cancer patient in Canada and worldwide.
Competitiondate
202209
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Wang, Zongjie
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~